Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
CYP2C19 encodes a member of the cytochrome P450 superfamily of enzymes. De plus, nous expédions CYP2C19 Anticorps (39) et CYP2C19 Protéines (3) et beaucoup plus de produits pour cette protéine.
Showing 4 out of 20 products:
appears that 5azaDC treatment affects an unidentified upstream regulator of both CYP2C19 and/or NR1I3 (Montrer NR1I3 Kits ELISA). This is supported by the fact that the relationships between TF for CYP2C19 and the expression of this target gene in human liver samples only accounted for approximately 70% of the variability of CYP2C19 mRNA levels.
For percutaneous coronary intervention in postoperative patients, research data is still lacking regarding clopidogrel dosage on the basis of different CYP2C19 genotypes.
Even heterozygous CYP2C19*2 allele carriers among Caucasian patients after ischemic stroke had a higher risk of major adverse clinical events.
results obtained from this study have proven the CYP (Montrer PPIG Kits ELISA) variants to be immunoreactive and spectrally active and are suitable for use to examine biotransformation and interaction mechanism of the enzymes
Report association of CYP2C19 genotype with bleeding in Serbian STEMI patients who have undergone primary PCI (Montrer SERPINA5 Kits ELISA) and treatment with clopidogrel.
Personalized treatment with clopidogrel or ticagrelor based on CYP2C19 genotype status ultimately led to improved clinical outcomes in acute coronary syndrome patients treated with percutaneous coronary intervention.
CYP2C19*2 Polymorphism is associated with drug resistance in Breast Cancer.
Comparisons of pharmacokinetics of 25 substrates CYP2C9 (Montrer CYP2C9 Kits ELISA), CYP2C19, or CYP2D6 (Montrer CYP2D6 Kits ELISA) in healthy Chinese and European subjects (classified with same enzyme activity) suggest that, for most substrates, limited interethnic pharmacokinetic differences exist (according to the databases used in this study). (CYP2C9 (Montrer CYP2C9 Kits ELISA) = cytochrome P450 (Montrer CYP Kits ELISA) family 2 subfamily C (Montrer CYP Kits ELISA) member 9; CYP2D6 (Montrer CYP2D6 Kits ELISA) = cytochrome P450 (Montrer CYP Kits ELISA) family 2 subfamily D (Montrer CYP Kits ELISA) member 6)
We documented a different effect of CYP2C19 and P2Y12 (Montrer P2RY12 Kits ELISA) receptor polymorphisms on platelet reactivity and cardiovascular outcome in coronary artery disease patients after percutaneous coronary intervention on clopidogrel treatment. Importantly, increased platelet reactivity adversely affects the cardiovascular outcome independently of the studied polymorphisms.
CYP2C19*2 and elevated BMI are associated with clopidogrel HTPR. However, CYP2C19*2 genotyping doesn't predict clopidogrel response sufficiently.
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize many xenobiotics, including the anticonvulsive drug mephenytoin, omeprazole, diazepam and some barbiturates. Polymorphism within this gene is associated with variable ability to metabolize mephenytoin, known as the poor metabolizer and extensive metabolizer phenotypes. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24.
cytochrome P450 2C
, (R)-limonene 6-monooxygenase
, (S)-limonene 6-monooxygenase
, (S)-limonene 7-monooxygenase
, S-mephenytoin 4-hydroxylase
, cytochrome P-450 II C
, cytochrome P450 2C19
, cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19
, cytochrome P450-11A
, cytochrome P450-254C
, flavoprotein-linked monooxygenase
, mephenytoin 4'-hydroxylase
, mephenytoin 4-hydroxylase
, microsomal monooxygenase
, xenobiotic monooxygenase